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Obstructive sleep apnea (OSA) shares many cardiovascular risk factors with metabolic
syndrome, including obesity, hypertension, insulin resistance, and pro-inflammatory state.
This study aimed to examine the possible association of OSA severity with insulin
resistance, inflammation and the metabolic syndrome.
Ninety eight patients suspected for OSA (54.9713.1 years) were studied. Overnight
polysomnography and blood sampling was taken for glucose, insulin, high-density
lipoprotein(HDL)-cholesterol, triglycerides, high-sensitivity C-reactive protein (Hs-CRP),
and serum amyloid A (S-AA). Insulin resistance was estimated by the homeostatic model
assessment (HOMA). Each patient was assigned a metabolic score according to the number
of discrete components of metabolic syndrome identified, and categorized by OSA severity.
Nine patients had primary snoring, nine had mild, 27 moderate and 53 severe OSA.
Metabolic score increased from 1.5671.01 to 2.9271.20 with OSA severity (p ¼ 0.004),
and was correlated independently with apnea hypopnea index (AHI; r ¼ 0.432, p ¼ 0.001)
and with body mass index (BMI; r ¼ 0.518 p ¼ 0.001). Hs-CRP increased from 3.4474.25 to
5.8774.76mg/dL with OSA severity (p ¼ 0.066) and correlated with AHI (r ¼ 0.348;
p ¼ 0.002). Insulin resistance, correlated significantly with AHI (r ¼ 0.390 p ¼ 0.021).
Inflammation, insulin resistance and metabolic syndrome increase with OSA severity. The
number of cardinal features of metabolic syndrome increases with an increase in OSA
severity, regardless of the BMI.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Metabolic syndrome is a constellation of risk factors for
heart disease consisting of abdominal or central obesity,
hypertension, elevated triglyceride level, reduced high-
density lipoprotein (HDL)-cholesterol level, and elevated
fasting glucose level. These might be accompanied by a
proinflammatory state and a prothrombotic predisposition.1
The Joint Conference of the American Heart Association/
National Heart Lung Blood Institute has recognized cardio-
vascular disease as a major clinical outcome of metabolic
syndrome.
Obstructive sleep apnea (OSA) syndrome is a common
nocturnal respiratory disorder affecting up to 5% of
adults.2,3 Patients with OSA have been found to have
abnormalities of each of the components of metabolic
syndrome,4 in addition to a higher prevalence of insulin
resistance than healthy persons.5–9 A growing body of
evidence supports an association among OSA, metabolic
syndrome and cardiovascular morbidity.10–18 However, the
relative contribution of OSA per se to this association is not
clear considering that obesity may account for much of the
morbidity. Furthermore, the relationship of OSA with
metabolic syndrome as a complete entity rather than with
its individual components remains unclear.
The aim of this study, was to test the hypothesis that the
severity of OSA is correlated with the severity of the sum
components of metabolic syndrome.
Materials and methods
Study group
The study group consisted of 98 consecutive male patients
who were referred to our sleep laboratory for whole-night
polysomnography (Compumedics, E-series, Australia) be-
cause of suspected OSA. Each participant completed a
detailed questionnaire on current and past medical history,
atherosclerotic risk factors, and sleep quality/excessive
daytime sleepiness. Patients with a history of heart failure
(New York Heart Association class III–IV or ejection fraction
o35%), diabetes mellitus, chronic lung disease, inflamma-
tory bowel disease, collagen-associated disease, other acute
disease/situation, or any change in medication for a chronic
disease 6 months prior to the study were excluded. The
institutional Human Subjects Review Board approved the
study protocol, and all patients signed an informed consent
form.
Polysomnography
All participants underwent overnight polysomnography.
Bedtime was between 22:00 and 24:00 h, and waking time
was at 06:00 h. Sleep was staged manually using the method
of Rechtschaffen and Kales.19 Respiratory monitoring was
performed with oro-nasal pressure sensors, chest and
abdominal respiratory belts, and finger-pulse oximetry
(Compumedics, Australia). Oxygen desaturation was mea-
sured according to minimal saturation (SaO2min) and time
(in minutes) with oxygen saturation below 90% (SaO2_90).
Apnea was defined as a cessation in airflow of at least 10 s.Hypopnea was defined as a decrease in the amplitude of the
respiratory signal by at least 50% for a minimum of 10 s,
followed by either a 4% decrease in oxygen saturation or a
sign of electroencephalo-graphic arousal. The apnea hypop-
nea index (AHI) was calculated by dividing the total number
of hypopnea and apnea events by the total hours of sleep.
OSA was defined as an AHI of X5/h. For purposes of the
study, the patients were divided into three subgroups
according to OSA severity, as follows: mild OSA, 5pAHIo15;
moderate OSA, 15pAHIo30; severe OSA, AHIX30. Patients
with AHIo5 and snored were considered as primary snoring
(PS).Blood assays
Morning blood samples were collected after polysomnogra-
phy and stored at 80 1C until assayed. Plasma glucose and
lipid levels, fibrin level, erythrocyte sedimentation rate,
and cell blood count were measured with commercially
available kits. Plasma insulin was determined by the INSIK-5
radioimmunoassay kit (CIS, Gif sur Yvette, France). High-
sensitivity C-reactive protein (Hs-CRP) level was used as an
indicator of inflammation. The homeostasis assessment
model (HOMA) was used to calculate insulin resistance
according to the following formula20: HOMA ¼ fasting
plasma insulin (mU/mL) fasting plasma glucose (mg/dL)/
22.5.Metabolic score
The number of components of metabolic syndrome present
(metabolic score) was evaluated according to the diagnostic
criteria of the National Cholesterol Education Program/
Adult Treatment Panel III (NCEP/ATP III)1: (1) abdominal
obesity, i.e., waist circumference above 88 cm for women or
102 cm for men, or if these data were unavailable a body
mass index (BMI) of 25 kg/m2 or greater for women and
29 kg/m2 or greater for men, based on studies showing that
using BMI values yields the same prevalence of metabolic
syndrome in the population as waist circumference21; (2)
blood pressure of 130/85mmHg or greater or current use of
antihypertensive medications, (3) fasting triglyceride level
above 150mg/dL, (4) HDL-cholesterol below 50mg/dL for
women or 40mg/dL for men, (5) fasting blood glucose above
110mg/dL. Each participant was assigned a metabolic score
which was calculated by adding the number of positive
diagnostic criteria identified (range 0–5). A score ofX3 was
considered diagnostic of metabolic syndrome.1Statistical analysis
Univariate and multivariate analyses (ANOVA, chi-squared
test and Pearson correlation) were used to investigate the
association among the sleep parameters, metabolic profile,
epidemiologic data, and laboratory values. The Statistical
Package for the Social Sciences (SPSS-12) was used for data
handling and analysis. Probability values less than 0.05 were
considered statistically significant.
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The background, clinical, and laboratory data for the
patients are shown in Table 1.
Nine patients in the study group had mild OSA, 27
moderate OSA, and 53 severe OSA. Nine patients had an
AHI of o5 and diagnosed as PS. Minimal oxygen saturation
(SaO2min) decreased significantly with an increase in OSA
severity, from 91.378.5% in the patients with PS to
74.9712.3% in the patients with severe OSA, whereas
oxygen saturation below 90% (SaO2_90) increased with OSA
severity, from 0min in the PS subgroup to 88.97105.6min in
the severe-OSA subgroup (p ¼ 0.001 for both, Table 1).
The expression of all individual components of metabolic
syndrome, as well as the levels of each of the individual
components, increased with an increase in OSA severity; not
all the differences reached statistical significance (Table 1).
The rate of central obesity increased from 67% in the PS
subgroup to 91% in the severe-OSA subgroup (p ¼ 0.008),
and BMI increased from 26.3 to 31.5 kg/m2 (p ¼ 0.001); the
rate of elevated fasting glucose increased from 0% to 34%
(p ¼ 0.029), with an increase in measured levels from 89.2
to 108.7mg/dL (NS). There was a trend toward higher levels
of triglycerides, lower levels of HDL-cholesterol, and greater
hypertension with OSA severity (Table 1).Table 1 Clinical and laboratory characteristics of patients wit
OSA
Snorers Mild
N 9 9
Age (years) 48.1725.6 48.2712.9
BMI (kg/m2) 26.375.7 24.972.5
AHI (events/h) 3.473.2 12.071.5
SaO2 min (%) 91.378.5 87.876.9
SaO2_90 (min) 0 3.175.9
Laboratory values
Glucose (mg/dL) 88.2710.2 89.1714.4
Triglycerides (mg/dL) 132.7776.1 178.5793.3
Total chol. (mg/dL) 188.4739.5 198.4734.8
HDL-chol. (mg/dL) 48.8714.4 47.13710.5
Insulin (mI/mL) 24.5711.6 27.0715.6
HOMA 102.7757.1 121.6774.5
S-AA (mg/dL) 7.9378.34 7.0774.86
Hs-CRP (mg/dL) 3.4474.25 2.7772.82
Metabolic components and score
Hypertension 1 (13%) 3 (43%)
Central obesity 6 (67%) 4 (57%)
Elevated glucose 0 2 (22%)
High triglycerides 2 (22%) 5 (63%)
Reduced HDL-chol. 0 2 (22%)
Metabolic score 1.5671.01 1.7871.48
Metabolic syndrome 0 1 (11%)
BMI—body mass index; AHI—apnea hypopnea index.
SaO2min ¼ minimal oxygen saturation (%); SaO2_90 ¼ time (min) wit
HOMA ¼ homeostatic model assessment; S-AA ¼ serum aminoaminid
score ¼ sum of components characteristic of metabolic syndrome; mThe mean sum of components (metabolic score) increased
significantly with OSA severity, from 1.5671.01 in the PS
subgroup to 2.9271.20 in the severe-OSA subgroup
(p ¼ 0.004; Table 1, Fig. 1).
On correlation analyses, increase in the metabolic score
was accompanied by a significant increase in AHI and
decrease in SaO2min (ANOVA, p ¼ 0.01; p ¼ 0.03, respec-
tively). The metabolic score significantly correlated with
AHI and SaO2min (r ¼ 0.432, p ¼ 0.001; r ¼ 0.360,
p ¼ 0.001; respectively), and with BMI (r ¼ 0.518;
p ¼ 0.001). On multiple regression analysis, BMI and AHI
significantly predicted the metabolic score (model
r ¼ 0.550, p ¼ 0.003), with a clinically equal contribution
for both measures (partial correlation 0.344; 0.357, respec-
tively; Table 2). Age and oxygen saturation did not enter the
model.
The calculated insulin resistance (HOMA) correlated
significantly with the AHI (r ¼ 0.390, p ¼ 0.021; Fig. 2),
but not with oxygen measures. Hs-CRP, as an expression of
inflammation correlated with the AHI (r ¼ 0.348, p ¼ 0.002;
Fig. 3) and with SaO2min (r ¼ 0.340, p ¼ 0.002). However,
when adjusting for BMI, the correlation with AHI was
(r ¼ 0.225 p ¼ 0.053), and borderline when controlling the
metabolic score (r ¼ 0.207 p ¼ 0.07). On multiple regres-
sion analysis metabolic score was the only parameter toh OSA* by severity of disease and controls.
Moderate Severe P
27 53
55.7712.4 55.9713.6 0.105
28.974.5 31.575.3 0.001
21.874.6 57.2720.0 0.001
84.476.2 74.9712.3 0.001
23.3769.8 88.97105.6 0.001
101.9741.9 108.7742.6 0.339
214.97163.8 207.37119.3 0.433
207.2739.2 192.7732.9 0.395
44.878.2 43.5711.0 0.730
41.6717.3 49.6738.8 0.433
179.87152.7 239.27236.6 0.600
4.3773.357 5.5773.34 0.177
3.4972.83 5.8774.76 0.066
11 (41%) 30 (58%) 0.082
22 (82%) 48 (91%) 0.008
5 (18%) 18 (34%) 0.029
13 (48%) 34 (68%) 0.090
11 (39%) 25 (47%) 0.250
2.2171.34 2.9271.20 0.004
6 (21%) 16 (30%) 0.036
h oxygen saturation below 90%; HDL ¼ high-density lipoprotein;
ase A; Hs-CRP ¼ high-sensitivity C-reactive protein; metabolic
etabolic syndrome ¼ metabolic score of X3.
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Figure 2 Increase in insulin resistance (HOMA) by increase in
(mU/mL) fasting plasma glucose (mg/dL)/22.5.
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Figure 1 Increase in metabolic score by change in OSA severity
(ANOVA, p ¼ 0.001). 0 ¼ controls, 1 ¼ mild OSA, 2 ¼ moderate
OSA, 3 ¼ severe OSA.
Table 2 Multiple regression analysis predicting meta-
bolic score (p ¼ 0.003).
b coefficient p Partial correlation
Constant 0.558
BMI 0.358 0.026 0.344
AHI 0.332 0.038 0.357
R model ¼ 0.55; BMI—body mass index; AHI—apnea hypop-
nea index.
OSA and metabolic syndrome 1699predict Hs-CRP (R model 0.386 p ¼ 0.001). Serum aminoa-
minidase A levels showed no significant association with any
of the OSA measures, though it correlated significantly with
Hs-CRP (r ¼ 0.380, p ¼ 0.001).Discussion
Our study demonstrates that the presence of OSA was
associated independently, by degree of severity, to the
number of components of metabolic syndrome present, and
correlated with insulin resistance and inflammatory para-
meters (Hs-CRP). There is a growing body of evidence
supporting an association between OSA and metabolic
syndrome11–15 and, specifically, insulin resis-
tance.5,7–9,18,22–26 Although this association might be attri-
butable to BMI rather than to OSA per se, the added benefit
of OSA treatment by continuous positive airway pressure
(CPAP) on blood pressure,27 cardiovascular morbidity,14
nocturnal ischemic events,17 insulin resistance,9,28 inflam-
matory cytokines (interleukin-6, tumor necrosis factor
alpha, vascular endothelial growth factor,29,30 and CRP,31)
indicates otherwise. The effect of OSA was further
supported by the study of Harsch et al.28 which showed an
improvement in insulin resistance within two days of CPAP
treatment, much before any change in BMI could occur.
Almost all these studies considered the variables involved
in metabolic syndrome individually. Only a few investiga-
tions to date have evaluated the association of OSA with
metabolic syndrome as a whole. Coughlin et al.23 in a sample
of 61 men with OSA and 43 control subjects, found that OSA
was independently associated with hypertension, high
fasting glucose and triglyceride levels, low HDL-cholesterol
level, and a trend toward high HOMA values, with an odds
ratio of 9.1 for total metabolic syndrome. However, they did50 75 100
AHI
AHI (r ¼ 0.390; p ¼ 0.021). HOMA—fasting plasma insulin
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Figure 3 Increase in Hs-CRP by change in AHI (mg/dL; r ¼ 0.348; p ¼ 0.002).
N. Peled et al.1700not focus on the severity of OSA. Lam et al.32 monitored 255
randomly selected Chinese volunteers for metabolic profile
and sleep characteristics by overnight polysomnography and
reported that OSA was associated with all the components of
metabolic syndrome, and that metabolic syndrome was an
independent predictor of OSA. The main value of the
present study is our finding that with an increase in the
severity of OSA, there is a significant increase in both the
incidence of metabolic syndrome and the number of its
components. Statistically significant differences were noted
for HOMA, Hs-CRP and fasting glucose, and a trend towards
an increase in hypertension and triglyceride level. These
results might explain the increased incidence of stroke and
fatal cardiovascular events in patients with severe OSA.14,15
The independent contribution of the AHI to the metabolic
score in our study is in agreement with the results of Marin
et al.14 showing that the increased cardiovascular morbidity
in OSA supercedes the effect of BMI and age. Our finding of
increased CRP with OSA severity is in agreement with
previous reports.31,33,34 However, its prediction by meta-
bolic score and not by OSA severity has not been reported
earlier. This might indicate that in the view of inflammation,
studies should be adjusted for metabolic score/syndrome
and not only to BMI in order to understand the isolated role
of OSA.
Oxygen saturation was correlated significantly with the
metabolic score, but it was not a significant predictor of the
metabolic score on multivariate regression analysis. This
finding is in agreement with the study of Makino et al.8 of
213 patients with OSA which showed that AHI, but not
oxygen saturation, predicted insulin resistance. However, Ip
et al.7 who followed 270 patients of whom 185 had OSA,
reported that besides obesity, both AHI and oxygen satura-
tion where independent determinants of insulin resistance.
Punjabi et al.5 in a cohort of 150 patients, showed that after
adjustment for BMI and AHI, for every 4% decrease in
SaO2min, the odds of having glucose tolerance increased by1.99. We believe that even though oxygen saturation did not
enter the prediction equation in our study, hypoxia plays a
significant role in the pathogenesis of OSA through oxidative
stress35–37 and inflammatory pathways.38
This study has some potential limitations. It is cross-
sectional study, therefore indicates association and not
causation; we used BMI and not central obesity for assessing
metabolic profile and finally the groups were not BMI
matched. In order to overcome the latter limitation we
used logistic and partial regression analysis.
In summary, OSA per se has a significant role in the
occurrence and the severity of metabolic syndrome, but its
isolated contribution to inflammation should be further
studied. The relative impact of the AHI on insulin resistance
and metabolic score is apparently greater than that of
oxygen desaturation.
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